PDE4DIP

PDE4DIP (myomegalin) is a Golgi-associated scaffolding protein that spatially organizes cyclic AMP/PKA signaling and additional growth and cytoskeletal pathways at the Golgi apparatus (PMID:34289528, PMID:39905234). It compartmentalizes PKA activity by anchoring the phosphodiesterase PDE4D, and a disease-associated mutation (p.A123T) that disrupts PDE4D colocalization raises cAMP and shifts PKA phosphorylation, increasing phosphorylation of the β2-adrenergic receptor while reducing phosphorylation of desmin; this scaffold defect interacts epistatically with a desmin (DES p.S13F) mutation to drive familial atrial fibrillation and conduction disease (PMID:34289528). Acting together with AKAP9, PDE4DIP retains and stabilizes the PKA regulatory subunit RIIα at the Golgi, so that its loss mislocalizes and degrades RIIα, derepressing PKA/CREB signaling and triggering apoptosis and cell cycle arrest (PMID:39905234). Beyond PKA, PDE4DIP recruits PLCγ/PKCε to the Golgi to drive constitutive PKCε activation and degradation of the RAS-GAP NF1, thereby sustaining oncogenic RAS/ERK signaling in KRAS-mutant colorectal cancer cells (PMID:37355626), and it negatively regulates the Rho-ROCK pathway to control cytoskeletal organization, cell polarity, migration, and energy metabolism in cardiomyocytes (PMID:40612665).

1. 2021 Medium

   Established PDE4DIP as a cAMP/PKA compartmentalization scaffold whose disruption rewires PKA substrate phosphorylation and, in epistasis with desmin, causes cardiac arrhythmia, defining its first disease-linked mechanism.

   Evidence Functional characterization of the PDE4DIP p.A123T mutant (colocalization, cAMP, PKA phosphorylation assays) plus exome sequencing and epistasis analysis in familial atrial fibrillation kindreds

   PMID:34289528

   Open questions at the time

   • Structural basis of PDE4D/PDE4DIP binding not resolved
   • Direct demonstration that the AF phenotype is reversed by restoring scaffolding is absent
   • Mechanism linking altered β2-AR/desmin phosphorylation to arrhythmia not fully traced
2. 2023 Medium

   Extended PDE4DIP function beyond PKA by showing it recruits PLCγ/PKCε to the Golgi to degrade NF1 and sustain RAS/ERK signaling, implicating it in KRAS-mutant cancer growth.

   Evidence Knockdown in colorectal cancer cell lines with RAS/ERK readouts, NF1 expression analysis, and Golgi localization assays for PLCγ/PKCε

   PMID:37355626

   Open questions at the time

   • Direct physical interaction between PDE4DIP and PLCγ/PKCε not biochemically defined
   • Mechanism of PKCε-dependent NF1 degradation unresolved
   • Single lab, in vitro only
3. 2025 Medium

   Defined the PDE4DIP-AKAP9 partnership as the basis for Golgi retention and stability of PKA RIIα, showing PDE4DIP loss derepresses PKA/CREB signaling to drive apoptosis and cell cycle arrest in NSCLC.

   Evidence PDE4DIP knockdown in NSCLC cells with co-IP/interaction assays, RIIα localization/stability assays, PKA/CREB readouts, and in vivo tumorigenicity

   PMID:39905234

   Open questions at the time

   • Reciprocal validation of the PDE4DIP-AKAP9 interaction limited
   • Degradation pathway for mislocalized RIIα not identified
   • Context dependence versus cancer-promoting roles in CRC unexplained
4. 2025 Medium

   Identified PDE4DIP as a negative regulator of the Rho-ROCK pathway controlling cardiomyocyte cytoskeleton, polarity, migration, and energy metabolism.

   Evidence Overexpression and knockdown in H9C2 cells and neonatal rat cardiomyocytes with EM, MitoTracker, ATP assays, immunofluorescence, and migration/proliferation assays

   PMID:40612665

   Open questions at the time

   • Direct molecular link between PDE4DIP and Rho-ROCK components not established
   • Whether this connects to its PKA scaffolding role is unknown
   • No in vivo cardiac validation
5. 2025 Low

   Placed PDE4DIP under post-transcriptional control by miR-21-5p, framing it as a tumor suppressor in NSCLC within a SORBS2/miR-21-5p axis.

   Evidence Luciferase reporter validation of miR-21-5p targeting, siRNA knockdown, miRNA mimic/inhibitor experiments, and xenograft tumor growth

   PMID:41378000

   Open questions at the time

   • Mechanistic detail on how PDE4DIP loss drives tumorigenesis not resolved
   • Single lab, single study
   • Apparent contradiction with PDE4DIP loss being pro-apoptotic in NSCLC (#2) not reconciled

• It remains unknown how PDE4DIP's distinct activities — PKA/PDE4D scaffolding, PLCγ/PKCε recruitment, and Rho-ROCK regulation — are integrated at the Golgi and why its loss is tumor-suppressive in some contexts yet its scaffolding sustains oncogenic signaling in others.
• No unified structural/domain map of binding partners
• Context-dependent tumor suppressor versus oncogenic roles unreconciled
• Centrosome-associated functions not addressed in the corpus